Month: August 2021

Galafold® is the First and Only Oral Therapy Approved in the EU for the Long-term Treatment of Adolescents with Fabry Disease Aged 12 years and older with an Amenable Mutation PHILADELPHIA, Aug. 02, 2021 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced the European Commission has approved Galafold® (migalastat) for use in adolescents aged 12 to

Second quarter 2021 revenue represents 17% total and 26% organic year over year growth, with 2021 third quarter mid-range revenue guidance of 24% total and 38% organic year over year growth MIGDAL HAEMEK, Israel, Aug. 02, 2021 (GLOBE NEWSWIRE) — Tower Semiconductor (NASDAQ: TSEM & TASE: TSEM) reports today its results for the second quarter ended June 30, 2021. HighlightsSecond quarter revenue of $362 million, reflecting record revenue for the company, with year over year 26% organic growth and 17% total growth. Significant year over year increases in gross profit, operating profit, and net profit. Guides mid-range revenue for the third quarter of 2021 of $385 million, demonstrating 24% year over year growth and 38% organic growth. Expanding the previously announced capacity expansion plan by an additional $100 million,...

The ADC is Expected to Accelerate Development and Clinical Manufacturing of Vaccines, Including Vaccines for COVID-19, When Fully Operational CHATHAM, N.J., Aug. 02, 2021 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it will hold a groundbreaking ceremony at the Company’s planned 45,000 square foot clinical scale manufacturing facility in the New Bedford Business Park in Massachusetts on August 3, 2021 at 11:00 a.m. ET. The new facility is expected to house Tonix’s Advanced Development Center (ADC) for accelerated research, development and analytical capabilities, as well as the production of clinical trial quality vaccines for infectious diseases, including COVID-19. The ceremony marks the formal start of site construction....

GREENWICH, Conn. , Aug. 02, 2021 (GLOBE NEWSWIRE) — XPO Logistics, Inc. (NYSE: XPO) today announced that it has completed the previously announced spin-off of GXO Logistics, Inc., creating two independent, publicly traded companies. XPO is a leading provider of freight transportation services, primarily less-than-truckload transportation and truck brokerage services, and GXO is the largest pure-play contract logistics provider in the world. XPO shares will continue to trade on the New York Stock Exchange under the symbol “XPO” and, effective today, GXO will begin “regular way” trading on the NYSE under the symbol “GXO.” Brad Jacobs, chairman and chief executive officer of XPO Logistics, said, “With the timely completion of our spin-off, XPO and GXO are moving forward with powerful momentum as independent public companies. I want...

Former Microsoft Azure founding member and Starbucks Executive to Accelerate R1’s Digital Growth and Innovation MURRAY, Utah, Aug. 02, 2021 (GLOBE NEWSWIRE) — R1 RCM Inc. (NASDAQ:RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced that Jay Sreedharan will join the executive team as its first chief technology and digital officer. Sreedharan will lead R1’s efforts in creating digital solutions that drive higher-value experiences for patients and providers. In this role, Sreedharan will be responsible for delivering on R1’s promise of digital transformation and growth, including strategy, engineering, product development, architecture and implementation, as well as future digital M&A and partnership activity. Sreedharan...

AUSTIN, Texas and NEW YORK, Aug. 02, 2021 (GLOBE NEWSWIRE) — AutoLotto, Inc. (“Lottery.com”), a leading technology company that is transforming how, where and when the lottery is played and Trident Acquisitions Corp. (Nasdaq: TDACU, TDAC, TDACW) (“Trident”) today provided business update, available on Lottery.com’s Investor Relations website here. Additionally, Lottery.com provided preliminary results for second quarter 2021 revenue, which is expected to be between $9.1 million and $9.6 million on a reported basis and between $10.0 million and $10.5 million on a pro forma basis including the recently acquired interests in Juega Lotto and Aganar. This compares to $0.9 million on a reported basis in the second quarter of 2020. During the last four quarters ended June 30, 2021, sequential revenue growth averaged approximately 87%...

LONDON, Aug. 02, 2021 (GLOBE NEWSWIRE) — OKYO Pharma Limited (the “Company”) is pleased to announce its final audited results for the year ended 31 March 2021. Summary of OKYO-101 studies during the last yearOK-101 is designed to target a chemokine-like receptor 1, or CMKLR1, which is a G protein-coupled receptor, or GPCR, expressed on macrophages, monocytes, plasmacytoid/myeloid dendritic cells, natural killer cells and nonhemopoietic cell types, such as endothelial and epithelial cells. Activation of CMKLR1 by its endogenous peptide ligand chemerin is known to modulate inflammation, but natural ligands for CMKLR1 have short half-lives due to rapid inactivation. To characterize the potential efficacy of OK-101 to treat DED, OK-101 was tested in a mouse model of acute dry eye disease induced with scopolamine that showed an increase...

To NASDAQ Copenhagen   Executive Board Lersø Parkallé 100 DK-2100 København Ø www.rd.dk Telephone +45 7012 5300 Telefax +45 4514 9622 2 August 2021  Prepayments, Realkredit Danmark A/S Pursuant to §24 of the Capital Markets Act, Realkredit Danmark A/S hereby publishes prepayments as at Friday 30 July 2021. Please find the data in the attached file. The information will also be available on www.rd.dk.   Yours sincerely The Executive Board   Any additional questions should be addressed to Hella Gebhardt Rønnebæk, Chief Analyst, phone +45 4513 2068.      AttachmentsNr. 67_Ekstraordinaere indfrielser pr. 30.07.2021_ukBilag til selskabsmeddelelse nr. 67-2021

Company Also Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) RESEARCH TRIANGLE PARK, N.C., Aug. 02, 2021 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the appointment of Andrew Perry as its Chief Commercial Officer (CCO). Mr. Perry replaces Soma Gupta who has left the Company for personal and professional reasons. “As we continue to evolve as a commercial company and execute on the launch of COSELA™ (trilaciclib), we are excited to announce the addition of Andrew to the G1 Therapeutics Executive Team,” said Jack Bailey, Chief Executive Officer of G1 Therapeutics. “Andrew is a proven leader and strategist with a history of driving consistent performance and commercial success; his extensive capabilities and depth of experience in launching and growing...

CONSHOHOCKEN, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet medical need, announced today that Dr. Robert Waltermire has joined Madrigal as Chief Pharmaceutical Development Officer. “We are pleased to announce that Dr. Robert Waltermire has joined the Madrigal R&D team. With over 30 years of experience in pharmaceutical development, Rob brings proven expertise in all aspects of chemistry, manufacturing and control (CMC) as well as experience in manufacturing new commercial products,” stated Becky Taub, M.D., President R&D and CMO of Madrigal. Paul Friedman, CEO of Madrigal added, “We look forward to reconnecting with Rob at Madrigal after having worked with him at...